We are live on ! Find out more
Cambridge Investment Research Advisors

Cambridge Investment Research Advisors Portfolio holdings

AUM $44.6B
1-Year Est. Return 28.94%
This Fund
S&P 500
This Quarter Est. Return
+6.8%
1 Year Est. Return
+28.94%
3 Year Est. Return
+82.62%
5 Year Est. Return
+90.41%
10 Year Est. Return
+293.66%
AUM
$20.4B
AUM Growth
+$1.11B
Cap. Flow
+$100M
Cap. Flow %
0.49%
Top 10 Hldgs %
18.19%
Holding
3,316
New
217
Increased
1,367
Reduced
1,468
Closed
167

Sector Composition

Rank Sector Weight
1 Technology 9.45%
2 Financials 4.68%
3 Healthcare 4.07%
4 Consumer Discretionary 3.92%
5 Industrials 2.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
SLDP icon
3076
Solid Power
SLDP
$536M
$32K ﹤0.01%
10,546
+430
+4% +$1.3K
LEV
3077
DELISTED
The Lion Electric Company
LEV
$32K ﹤0.01%
+17,424
New +$39.4K
OMIC
3078
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
$32K ﹤0.01%
+878
New +$53.8K
GNSS icon
3079
Genasys
GNSS
$77.4M
$31K ﹤0.01%
10,410
XXII
3080
22nd Century Group
XXII
$1.49M
0
UP icon
3081
Wheels Up
UP
$190M
$29K ﹤0.01%
228
-1
-0.4% -$222
ZEV
3082
DELISTED
Lightning eMotors, Inc.
ZEV
$29K ﹤0.01%
5,007
-68
-1% -$793
HRTX icon
3083
Heron Therapeutics
HRTX
$64.7M
$27K ﹤0.01%
18,017
+700
+4% +$1.75K
SNDL icon
3084
Sundial Growers
SNDL
$313M
$27K ﹤0.01%
16,980
VAXX
3085
DELISTED
Vaxxinity, Inc. Class A Common Stock
VAXX
$27K ﹤0.01%
12,000
BBIG
3086
DELISTED
Vinco Ventures, Inc. Common Stock
BBIG
$27K ﹤0.01%
4,210
-765
-15% -$8.1K
LFMD icon
3087
LifeMD
LFMD
$159M
$26K ﹤0.01%
15,200
REFR icon
3088
Research Frontiers
REFR
$16.8M
$26K ﹤0.01%
15,166
SONX
3089
DELISTED
Sonendo, Inc.
SONX
$26K ﹤0.01%
12,980
IBRX icon
3090
ImmunityBio
IBRX
$8.2B
$25K ﹤0.01%
13,950
+2,000
+17% +$6.22K
REKR icon
3091
Rekor Systems
REKR
$94M
$25K ﹤0.01%
19,689
-2,000
-9% -$3.18K
XOS icon
3092
Xos
XOS
$36.1M
$25K ﹤0.01%
+1,583
New +$37.2K
HUT
3093
Hut 8
HUT
$11.2B
$24K ﹤0.01%
2,605
-100
-4% -$850
NAK
3094
Northern Dynasty Minerals
NAK
$953M
$23K ﹤0.01%
97,160
+25,000
+35% +$5.76K
CRDL
3095
Cardiol Therapeutics
CRDL
$175M
$22K ﹤0.01%
+46,011
New +$27.2K
AEY
3096
DELISTED
ADDvantage Technologies Group
AEY
$22K ﹤0.01%
+2,000
New +$28.2K
BDTX icon
3097
Black Diamond Therapeutics
BDTX
$121M
$21K ﹤0.01%
11,231
GEVO icon
3098
Gevo
GEVO
$391M
$21K ﹤0.01%
13,448
+1,700
+14% +$3.22K
REI icon
3099
Ring Energy
REI
$354M
$21K ﹤0.01%
11,000
-5,579
-34% -$12K
MNTS icon
3100
Momentus
MNTS
$91.5M
$20K ﹤0.01%
3

Similar funds

Cambridge Investment Research Advisors's Q1 2023 Portfolio in Review

As of Q1 2023, Cambridge Investment Research Advisors held 3,316 positions worth $20.4B, up 5.8% from $19.3B the previous quarter. Its ten largest holdings account for 18% of the portfolio.

Cambridge Investment Research Advisors's Q1 2023 filing shows 217 new, 1,367 increased, 1,468 reduced and 167 closed positions. Its largest new stake was State Street SPDR Bloomberg International Treasury Bond ETF: 735,671 shares worth $17M. The largest sale was iShares 0-1 Year Treasury Bond ETF, an estimated $44.6M.

By sector, the portfolio is most concentrated in Technology at 9.4% of assets, up from 8% a quarter earlier, followed by Financials and Healthcare.

  • Cambridge Investment Research Advisors's largest Q1 2023 buy was State Street SPDR Bloomberg International Treasury Bond ETF: 735,671 shares worth $17M.
  • Cambridge Investment Research Advisors added most to State Street SPDR Bloomberg 1-3 Month T-Bill ETF in Q1 2023, an estimated $43.9M increase.
  • Cambridge Investment Research Advisors's biggest Q1 2023 reduction was iShares 0-1 Year Treasury Bond ETF, cutting an estimated $44.6M.
  • Cambridge Investment Research Advisors fully exited ProShares Short Russell2000 in Q1 2023, selling an estimated $4.61M.
  • Cambridge Investment Research Advisors's ten largest holdings make up 18% of its $20.4B portfolio in Q1 2023.
  • Cambridge Investment Research Advisors opened 217 new positions and closed 167 in Q1 2023.
  • Cambridge Investment Research Advisors's portfolio value rose 5.8% quarter-over-quarter to $20.4B.

Based on Cambridge Investment Research Advisors's 13F filing for Q1 2023, filed 11 May 2023.